• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Ligand Pharmaceuticals agrees to acquire Pfenex for $516m pharmaceutical-technology
    August 12, 2020
    Ligand Pharmaceuticals has entered into a definitive agreement to acquire development and licencing biotechnology firm Pfenex in a deal valued at approximately $516m.
  • Deals this week: Mundipharma, Ligand Pharmaceuticals pharmaceutical-technology
    November 25, 2018
    Kolon Life Sciences dosed the first patient in a Phase III trial for Invossa this month. It is hoping to be granted the US Food and Drug Administration’s (FDA) Disease Modifying Osteoarthritis Drug (DMOAD) label.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service